← Back to signals

Public Event Detail

28,037 Shares in CRISPR Therapeutics AG $CRSP Bought by Blue Jean Financial LLC

Public historical observation from the Merrowstone archive. This page shows event-level context only. Accepted assertions, evidence lineage, and relationship intelligence remain part of the premium research layer.

Historical observations only. No forecasts, recommendations, buy/sell ratings, or portfolio advice.
2026-06-14JPMJPMorgan ChaseAlpha Vantage Newsearnings

Event summary

Blue Jean Financial LLC initiated a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) during the fourth quarter, purchasing 28,037 shares valued at approximately $1.47 million. Institutional investment in CRISPR Therapeutics remains robust, with hedge funds and other investors holding 69.20% of the company's stock, including significant increases from JPMorgan Chase & Co. and UBS Group AG. Despite reporting a quarterly loss of $1.28 per share and limited revenue, analysts maintain a "Moderate Buy" rating with an average price target of $67.78.

Attached public signals

Observed outcomes

7d returnPending
30d returnPending
90d returnPending
Relative 90d returnPending

Archive metadata

Legacy event IDevt_21a9cb1d075e1d721f36
Importance score0.00
Materiality score0.00
Categoryalpha_vantage_news
Source archetypehistorical_news
Created2026-06-15T17:21:16+00:00